Translating slow-binding inhibition kinetics into cellular and in vivo effects

Nature Chemical Biology

Volumn 11, Issue 6, 2015, Pages 416-423

  Walkup, Grant K ^a,c   You, Zhiping ^a   Ross, Philip L ^a   Allen, Eleanor K H ^b   Daryaee, Fereidoon ^b   Hale, Michael R ^a   O'Donnell, John ^a   Ehmann, David E ^a   Schuck, Virna J A ^a   Buurman, Ed T ^a   Choy, Allison L ^a   Hajec, Laurel ^a   Murphy Benenato, Kerry ^a   Marone, Valerie ^a   Patey, Sara A ^a   Grosser, Lena A ^a   Johnstone, Michele ^a   Walker, Stephen G ^b   Tonge, Peter J ^b   Fisher, Stewart L ^a  

^a ASTRAZENECA   (United Kingdom)

^b STONY BROOK UNIVERSITY   (United States)

^c AGIOS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDASE; ANTIINFECTIVE AGENT; CHIR 090; ENZYME INHIBITOR; HYDROXAMIC ACID; LPXC DEACETYLASE, PSEUDOMONAS; PROTEIN BINDING; THREONINE;

ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; INBRED MOUSE STRAIN; KINETICS; MICROBIAL SENSITIVITY TEST; PSEUDOMONAS AERUGINOSA; TIME FACTOR;

AMIDOHYDROLASES; ANIMALS; ANTI-BACTERIAL AGENTS; ENZYME INHIBITORS; HYDROXAMIC ACIDS; KINETICS; MICE, INBRED STRAINS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; PROTEIN BINDING; PSEUDOMONAS AERUGINOSA; THREONINE; TIME FACTORS;

EID: 84937760572     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1796     Document Type: Article

References (58)

1. Arrowsmith, J. Trial watch: Phase II failures: 2008-2010. Nat. Rev. Drug Discov. 10, 328-329 (2011).
2. Cook, D. et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat. Rev. Drug Discov. 13, 419-431 (2014).
3. Morgan, P. et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov. Today 17, 419-424 (2012).
4. Swinney, D.C. Biochemical mechanisms of new molecular entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and safety. Curr. Top. Med. Chem. 6, 461-478 (2006).
5. Swinney, D.C. The role of binding kinetics in therapeutically useful drug action. Curr. Opin. Drug Discov. Devel. 12, 31-39 (2009).
6. Copeland, R.A., Pompliano, D.L. & Meek, T.D. Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug Discov. 5, 730-739 (2006).
7. Copeland, R.A. The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety. Expert Opin. Drug Discov. 5, 305-310 (2010).
8. Lu, H. & Tonge, P.J. Drug-target residence time: critical information for lead optimization. Curr. Opin. Chem. Biol. 14, 467-474 (2010).
9. Drusano, G.L. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat. Rev. Microbiol. 2, 289-300 (2004).
10. Hickey, E. Tools to define the relevance of PK/PD parameters to the efficacy, toxicity and emergence of resistance of antimicrobials. Curr. Opin. Drug Discov. Devel. 10, 49-52 (2007).
11. McKenzie, C. Antibiotic dosing in critical illness. J. Antimicrob. Chemother. 66 (suppl. 2): ii25-ii31 (2011).
12. Barb, A.W. & Zhou, P. Mechanism and inhibition of LpxC: an essential zinc-dependent deacetylase of bacterial lipid A synthesis. Curr. Pharm. Biotechnol. 9, 9-15 (2008).
13. Bundtzen, R.W., Gerber, A.U., Cohn, D.L. & Craig, W.A. Postantibiotic suppression of bacterial growth. Rev. Infect. Dis. 3, 28-37 (1981).
14. Gennadios, H.A. & Christianson, D.W. Binding of uridine 5′-diphosphate in the 'basic patch' of the zinc deacetylase LpxC and implications for substrate binding. Biochemistry 45, 15216-15223 (2006).
15. Gennadios, H.A., Whittington, D.A., Li, X., Fierke, C.A. & Christianson, D.W. Mechanistic inferences from the binding of ligands to LpxC, a metal-dependent deacetylase. Biochemistry 45, 7940-7948 (2006).
16. Morrison, J.F. & Walsh, C.T. The behavior and significance of slow-binding enzyme inhibitors. Adv. Enzymol. 61, 201-301 (1988).
17. Zhang, R. & Windsor, W.T. In vitro kinetic profiling of Hepatitis C virus NS3 protease inhibitors by progress curve analysis. Methods Mol. Biol. 1030, 59-79 (2013).
18. Copeland, R.A. Evaluation of Enzyme Inhibitors in Drug Discovery: a Guide for Medicinal Chemists and Pharmacologists (Wiley, 2013).
19. Vauquelin, G. Rebinding: or why drugs may act longer in vivo than expected from their in vitro target residence time. Expert Opin. Drug Discov. 5, 927-941 (2010).
20. Tummino, P.J. & Copeland, R.A. Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry 47, 5481-5492 (2008).
21. Copeland, R.A., Basavapathruni, A., Moyer, M. & Scott, M.P. Impact of enzyme concentration and residence time on apparent activity recovery in jump dilution analysis. Anal. Biochem. 416, 206-210 (2011).
22. Williams, J.W. & Morrison, J.F. The kinetics of reversible tight-binding inhibition. Methods Enzymol. 63, 437-467 (1979).
23. Morrison, J.F. Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochim. Biophys. Acta 185, 269-286 (1969).
24. 50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099-3108 (1973).
25. Chang, A. et al. Rational optimization of drug-target residence time: insights from inhibitor binding to the Staphylococcus aureus FabI enzyme-product complex. Biochemistry 52, 4217-4228 (2013).
26. Masuda, N. et al. Substrate substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM efflux pumps in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44, 3322-3327 (2000).
27. Fung-Tomc, J.C., Gradelski, E., Valera, L., Kolek, B. & Bonner, D.P. Comparative killing rates of fluoroquinolones and cell wall-active agents. Antimicrob. Agents Chemother. 44, 1377-1380 (2000).
28. Mdluli, K.E. et al. Molecular validation of LpxC as an antibacterial drug target in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50, 2178-2184 (2006).
29. Spangler, S.K., Bajaksouzian, S., Jacobs, M.R. & Appelbaum, P.C. Postantibiotic effects of grepafloxacin compared to those of five other agents against 12 Gram-positive and -negative bacteria. Antimicrob. Agents Chemother. 44, 186-189 (2000).
30. Mager, D.E., Wyska, E. & Jusko, W.J. Diversity of mechanism-based pharmacodynamic models. Drug Metab. Dispos. 31, 510-518 (2003).
31. Czock, D. & Keller, F. Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects. J. Pharmacokinet. Pharmacodyn. 34, 727-751 (2007).
32. Bennett, B.D. et al. Absolute metabolite concentrations and implied enzyme active site occupancy in Escherichia coli. Nat. Chem. Biol. 5, 593-599 (2009).
33. Taber, H.W., Mueller, J.P., Miller, P.F. & Arrow, A.S. Bacterial uptake of aminoglycoside antibiotics. Microbiol. Rev. 51, 439-457 (1987).
34. Nikaido, H. & Thanassi, D.G. Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples. Antimicrob. Agents Chemother. 37, 1393-1399 (1993).
35. Montgomery, J.I. et al. Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious Gram-negative infections. J. Med. Chem. 55, 1662-1670 (2012).
36. Smith, H. Pathogenicity and the microbe in vivo. J. Gen. Microbiol. 136, 377-393 (1990).
37. DiMasi, J.A., Feldman, L., Seckler, A. & Wilson, A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin. Pharmacol. Ther. 87, 272-277 (2010).
38. Mager, D.E. Target-mediated drug disposition and dynamics. Biochem. Pharmacol. 72, 1-10 (2006).
39. Yan, X., Mager, D.E. & Krzyzanski, W. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. J. Pharmacokinet. Pharmacodyn. 37, 25-47 (2010).
40. Caughlan, R.E. et al. Mechanisms decreasing in vitro susceptibility to the LpxC inhibitor CHIR-090 in the Gram-negative pathogen Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 56, 17-27 (2012).
41. Nikolaou, M., Schilling, A.N., Vo, G., Chang, K.T. & Tam, V.H. Modeling of microbial population responses to time-periodic concentrations of antimicrobial agents. Ann. Biomed. Eng. 35, 1458-1470 (2007).
42. Millan, D.S. et al. Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease. J. Med. Chem. 54, 7797-7814 (2011).
43. Cohen, S.B. et al. Evaluation of the efficacy and safety of Pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum. 60, 335-344 (2009).
44. Wood, E.R. et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 64, 6652-6659 (2004).
45. Daigle, S.R. et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 122, 1017-1025 (2013).
46. Liu, Q. et al. Developing irreversible inhibitors of the protein kinase cysteinome. Chem. Biol. 20, 146-159 (2013).
47. Schwarzbich, M.-A. & Witzens-Harig, M. Ibrutinib. in Small Molecules in Oncology (Recent Results Cancer Research, vol. 201) (ed. Martens, U.M.) 259-267 (Springer, 2014).
48. Gao, N. et al. Overexpression of Pseudomonas aeruginosa LpxC with its inhibitors in an acrB-deficient Escherichia coli strain. Protein Expr. Purif. 104C, 57-64 (2014).
49. Takashima, H. et al. Preparation of quinoline-4-carbohydroxamic acid and naphthyridine-4-carbohydroxamic acid derivatives as antibacterial agents. PCT Int. Appl. WO2008105515A1 (2008).
50. Hale, M.R. et al. Exploring the UDP pocket of LpxC through amino acid analogs. Bioorg. Med. Chem. Lett. 23, 2362-2367 (2013).
51. CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Ninth Edition. CLSI Doc. M07-A9. Clinical Laboratory Standards Institute, Wayne, PA. (2012).
52. West, S.E.H., Schweizer, H.P., Dall, C., Sample, A.K. & Runyen-Janecky, L.J. Construction of improved Escherichia-Pseudomonas shuttle vectors derived from pUC18/19 and sequence of the region required for their replication in Pseudomonas aeruginosa. Gene 148, 81-86 (1994).
53. Choi, K.-H., Kumar, A. & Schweizer, H.P. A 10-min method for preparation of highly electrocompetent Pseudomonas aeruginosa cells: application for DNA fragment transfer between chromosomes and plasmid transformation. J. Microbiol. Methods 64, 391-397 (2006).
54. Gudmundsson, S., Vogelman, B. & Craig, W. A. The in vivo postantibiotic effect of imipenem and other new antimicrobials. J. Antimicrob. Chemother. 18 (suppl. E): 67-73 (1986).
55. Parker, R.F. & Marsh, H.C. The action of penicillin on Staphylococcus. J. Bacteriol. 51, 181-186 (1946).
56. de Jonge, B.L.M. et al. Discovery of inhibitors of 4′-phosphopantetheine adenylyltransferase (PPAT) to validate PPAT as a target for antibacterial therapy. Antimicrob. Agents Chemother. 57, 6005-6015 (2013).
57. Kariv, I., Cao, H. & Oldenburg, K.R. Development of a high throughput equilibrium dialysis method. J. Pharm. Sci. 90, 580-587 (2001).
58. Gerber, A.U. et al. Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice. J. Infect. Dis. 147, 910-917 (1983).